CONOCOPHILLIPS — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CONOCOPHILLIPS filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.94B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $54.75B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $56.14B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $78.49B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $45.83B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $18.78B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $36.67B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $38.73B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $32.58B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $24.36B | Feb 19, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.82B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $49.42B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $48.52B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $61.05B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $34.59B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $13.66B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $32.57B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $36.42B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $29.11B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $23.69B | Feb 19, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $29.11B | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | $23.69B | Feb 20, 2018 |
| FY2017 | Dec 31, 2015 | $29.56B | Feb 20, 2018 |
| FY2016 | Dec 31, 2014 | $52.52B | Feb 21, 2017 |
| FY2015 | Dec 31, 2013 | $54.41B | Feb 23, 2016 |
| FY2014 | Dec 31, 2012 | $57.97B | Feb 24, 2015 |
| FY2013 | Dec 31, 2011 | $64.20B | Feb 25, 2014 |
| FY2012 | Dec 31, 2010 | $56.22B | Feb 19, 2013 |
| FY2009 | Dec 31, 2009 | $149.34B | Feb 25, 2010 |
| FY2010 | Dec 31, 2008 | $240.84B | Feb 23, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.99B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $9.25B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $10.96B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $18.68B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $8.08B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | ($2.70B) | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $7.19B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $6.26B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | ($855.00M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | ($3.62B) | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $81.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $81.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $71.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $62.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $75.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $82.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $78.00M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $100.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $116.00M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $893.00M | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $1.16B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $705.00M | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $623.00M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $719.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $430.00M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $556.00M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $401.00M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $427.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $473.00M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.80B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $20.12B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $19.97B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $28.31B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $17.00B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $4.80B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $11.10B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $12.93B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $7.08B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $4.40B | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.94B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $122.78B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $95.92B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $93.83B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $90.66B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $62.62B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $70.51B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $69.98B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $73.36B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $89.77B | Feb 19, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.45B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $57.98B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $46.65B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $45.83B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $45.26B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $32.77B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $35.46B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $37.92B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $42.56B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $54.55B | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.49B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $64.80B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $49.28B | Feb 17, 2026 |
| FY2025 | Dec 31, 2022 | $48.00B | Feb 17, 2026 |
| FY2024 | Dec 31, 2021 | $45.41B | Feb 18, 2025 |
| FY2023 | Dec 31, 2020 | $29.85B | Feb 15, 2024 |
| FY2020 | Dec 31, 2019 | $34.98B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $31.94B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $30.61B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $34.97B | Feb 20, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $3.33B | Feb 21, 2012 |
| FY2010 | Dec 31, 2010 | $3.63B | Feb 23, 2011 |
| FY2009 | Dec 31, 2009 | $3.64B | Feb 25, 2010 |
| FY2009 | Dec 31, 2008 | $3.78B | Feb 25, 2010 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.86B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $64.87B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $59.27B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $53.03B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $40.67B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $35.21B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $39.74B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $34.01B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $29.39B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $31.55B | Feb 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.50B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $5.61B | Feb 17, 2026 |
| FY2024 | Dec 31, 2023 | $5.64B | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $6.46B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $5.03B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $2.99B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $5.09B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $5.92B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $6.33B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $3.61B | Feb 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $16.15B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $22.44B | Feb 19, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 14 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 6 | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | 5 | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | (2) | Feb 19, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | 7 | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | 14 | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | 6 | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | 6 | Feb 17, 2022 |
| FY2017 | Dec 31, 2017 | 0 | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | (2) | Feb 20, 2018 |
| FY2017 | Dec 31, 2015 | (3) | Feb 20, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.00B | Feb 17, 2026 |
| FY2025 | Dec 31, 2024 | $3.65B | Feb 17, 2026 |
| FY2025 | Dec 31, 2023 | $5.58B | Feb 17, 2026 |
| FY2024 | Dec 31, 2022 | $5.73B | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $2.36B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.83B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $1.50B | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $1.36B | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $1.31B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.25B | Feb 19, 2019 |